Comparative Pharmacology
Head-to-head clinical analysis: DRIZALMA SPRINKLE versus PRISTIQ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DRIZALMA SPRINKLE versus PRISTIQ.
DRIZALMA SPRINKLE vs PRISTIQ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective serotonin reuptake inhibition, resulting in increased synaptic serotonin concentrations and enhanced serotonergic neurotransmission.
Desvenlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI). It binds to the serotonin transporter (SERT) and norepinephrine transporter (NET), inhibiting reuptake of serotonin and norepinephrine, thereby increasing their synaptic concentrations.
60 mg orally once daily, with or without food. Capsules may be swallowed whole or opened and sprinkled onto applesauce.
50 mg orally once daily, with or without food; may increase by 50 mg every 7 days to a maximum of 100 mg once daily; maximum dose is 100 mg/day (some studies up to 400 mg/day but not recommended).
None Documented
None Documented
12-15 hours; steady-state achieved in 2-3 days; no significant accumulation with q12h dosing.
Desvenlafaxine: ~11 hours (range 8-15 h); supports once-daily dosing
Primarily renal (approx. 70% as unchanged drug and metabolites); 30% fecal/biliary.
Renal: 87% (45% desvenlafaxine unchanged, 42% as metabolites); biliary/fecal: minimal (<1%)
Category C
Category C
SNRI Antidepressant
SNRI Antidepressant